Trump DOJ efforts to block abortion pill challenges frustrate pro-life advocates
The Trump administration's Department of Justice is seeking to pause several state lawsuits aimed at rolling back eased restrictions on the abortion drug mifepristone. The DOJ is moving to dismiss lawsuits from states like Louisiana, Missouri, and Florida that challenge the FDA policy allowing mifepristone distribution by mail. States argue that the FDA's policy undermines their existing state laws regarding the drug. Pro-life advocates, including Susan B. Anthony Pro-Life America's president, have expressed frustration over the Trump-Vance DOJ actively opposing the challenges brought by pro-life states. DOJ lawyers have argued that courts should either stay the cases until the FDA completes its review or dismiss them, though the timeline for the FDA review remains unclear.
3 days ago
The Trump administration's Department of Justice has filed motions to pause or dismiss lawsuits from states like Louisiana, Missouri, and Florida challenging Biden-era FDA policies that allow mail-order distribution of mifepristone.1
DOJ argues courts should stay cases pending FDA review, though the review's status and timeline remain unclear.1
Pro-life leaders express strong disappointment with the Trump-Vance DOJ for opposing states enforcing their laws against mail-order abortion pills.1
Marjorie Dannenfelser of Susan B. Anthony Pro-Life America calls it "inexcusable," noting over 60% of abortions now involve chemical drugs prone to abuse.1
David Bereit of 40 Days for Life deems the DOJ efforts "concerning" and "troubling," urging prioritization of women's health over politics.1
Guttmacher Institute data shows 1,126,000 clinician-provided abortions in 2025, the highest since 2009.1
Dannenfelser highlights support from 51 senators, 175 House members, and 21 state AGs backing Louisiana's suit, plus polls favoring in-person doctor visits before chemical abortions.1
Reproductive Freedom for All defends mifepristone as safe after 20+ years, framing challenges as a nationwide abortion ban effort.1
Critics question FDA's approval of a new generic mifepristone amid ongoing safety reviews, seeing it as politically motivated.1
Sarah Zagorski of Americans United for Life hopes courts reject DOJ delays, prioritizing justice for women harmed by deregulation.1
The Catholic Church opposes abortion while emphasizing support for mothers and children post-Dobbs.1
Investigate Catholic doctrine on abortion drug regulation
Catholic teaching unequivocally condemns procured abortion as a grave moral evil, recognizing human life as sacred from the moment of conception. The Church teaches that direct abortion—willed either as an end or a means—is gravely contrary to the moral law, constituting the deliberate killing of an innocent human being. This doctrine, rooted in Scripture (e.g., Jer 1:5; Ps 139:15-16), natural law, Tradition, and the ordinary Magisterium, is unchangeable. Formal cooperation incurs latae sententiae excommunication (Canon 1398), affecting procurers and necessary accomplices who act with knowledge of the penalty.
"Human life must be respected and protected absolutely from the moment of conception... Direct abortion... is gravely contrary to the moral law."
The Catechism of the Catholic Church and parallel catechisms affirm this: abortion is the deliberate and direct killing of a human being from conception to birth, including actions destroying embryos via reproductive technologies. Vatican II's Gaudium et Spes (51) deems abortion and infanticide "abominable crimes," a stance reiterated by Popes Pius XI, Pius XII, John XXIII, Paul VI, and John Paul II.
Catholic health care institutions must never provide abortion services, even under material cooperation, defining abortion as the directly intended termination of pregnancy before viability or destruction of a viable fetus—including procedures ending pregnancy between conception and implantation.
Abortion drugs, such as mifepristone (used in chemical abortions), fall under this prohibition as they directly intend the destruction of embryonic or fetal life. Chemical abortion via mifepristone is a form of direct abortion, never morally licit, as it terminates the life willed by God. The Church rejects any circumstance justifying such intrinsically illicit acts.
Recent USCCB guidance highlights telemedicine chemical abortions using mifepristone, noting severe risks: a study of 865,727 cases (2017-2023) found 10.93% serious adverse events (infection, sepsis, hemorrhage, incomplete abortion)—22 times higher than FDA-acknowledged rates. Chemical abortions surged 137% since 2016, now 63% of U.S. abortions, often without oversight like in-person visits or ultrasounds.
Ethical violations include:
These drugs undermine human dignity, exploiting life's beginning rather than safeguarding it.
While doctrine forbids abortion outright, the Church engages civil authorities on regulation to protect women and the unborn. The USCCB urges the FDA to:
"The FDA has an ethical obligation to protect women from the dangers that mifepristone presents... Reinstating essential REMS safeguards... will better protect women's health."
Pope Leo XIV echoes this, rejecting public funding for "safe abortion" access and urging resources for mothers/families instead. Catholic entities oppose deregulating abortion drugs, prioritizing life's protection over ideology. Regulation should prevent scandal, coercion, and harm, fostering conversion paths for the repentant.
No sources endorse liberalization; all prioritize absolute protection of the unborn and maternal health.
Catholic doctrine deems abortion drugs like mifepristone gravely immoral as direct killers of innocent life, incurring excommunication. The Church advocates stricter regulation—not legalization—to mitigate health risks, ensure consent, and redirect resources toward life-affirming support, aligning with divine law and human dignity.